Flowonix Medical and Cerebral Therapeutics said today they signed a deal to develop an implanted brain-targeted drug delivery system to treat neurological diseases.
The device is being designed to deliver microdoses of medication directly to the brain, bypassing the blood-brain barrier and reaching specifically targeted regions for more effective dosing, Mount Olive, N.J.-based Flowonix said.
“Neurological disorders can be devastating to patients and their families, and patients are often left with few options. Flowonix has long been a world leader in implantable infusion systems and we have specific expertise in the accurate and reliable delivery of microdoses of medication. We are pleased to partner with Cerebral Therapeutics to bring this safe, effective, and successful drug delivery technology to one of the most challenging frontiers in medicine—the brain,” Flowonix CEO Steven Adler said in prepared remarks.
Flowonix develops drug delivery systems for treating chronic pain, and Cerebral Therapeutics is developing neurological microdosing systems, according to the companies.
“Cerebral Therapeutics chose to work with Flowonix because the Prometra and Prometra II infusion pumps offer a patented valve-gated drug delivery system which allows for very precise dosing of medicine. The state-of-the-art Prometra pump platform will be used to deliver medication directly to the brain. For certain agents, this may reduce the doses necessary for therapeutic effect, lessen the risk of systemic toxicity, and possibly ameliorate the side effects associated with certain types of neurological therapies, ” CEO Dr. Dan Abrams said in a press release.
In August, Flowonix Medical said it won FDA 510(k) clearance for its Patient Therapy Controller designed to interface with intrathecal infusion devices.
The PTC is a small hand-held device with a touch screen that allows patients to initiate bolus delivery of medication from implanted pumps, according to the Mount Olive, N.J.-based company. The device is designed to operate with the company’s Prometra platform of infusion devices.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.